Literature DB >> 24413224

Pain control in patients with hepatocellular carcinoma treated by percutaneous radiofrequency ablation: comparison of the efficacy of one-shot and continuous intravenous fentanyl delivery.

Koichi Yokoyama1, Osamu Ikeda2, Koichi Kawanaka1, Yutaka Nakasone1, Seijiro Inoue1, Yoshitaka Tamura1, Yasuyuki Yamashita1.   

Abstract

BACKGROUND: Hepatic percutaneous radiofrequency ablation (RFA) is usually performed with the patient under deep intravenous (i.v.) sedation or general anesthesia. Nonetheless, many patients report pain during and/or after the procedure.
PURPOSE: To perform a prospective study of pain control obtained by the i.v. one-shot delivery and the continuous i.v. infusion of fentanyl in patients with hepatocellular carcinoma (HCC) treated by RFA.
MATERIAL AND METHODS: Between April 2007 and March 2010, 83 patients with 106 HCCs underwent percutaneous RFA. All HCCs were addressed by computed tomography (CT)-guided percutaneous RFA performed within 5 h of embolization of the tumor vessels with iodized oil and gelatin sponges. Standard anesthesia consisted of 10 mL of 1% lidocaine injected locally. For conscious sedation, group one patients (n = 41) were injected i.v. with 100 µg of fentanyl before and 100 µg of fentanyl 30 min after percutaneous RFA. In group two (n = 42) we delivered fentanyl by continuous i.v. infusion at 100 µg/h during RFA. Upon request, patients in both groups also received 5 mg of diazepam i.v. for pain during the RFA procedure. The severity of pain experienced by all patients was evaluated on a visual analogue scale (VAS) and complications elicited by the anesthesia regimens were recorded. We also assessed the effectiveness of the treatment on sequential follow-up CT and/or magnetic resonance imaging (MRI) at 3-month intervals.
RESULTS: Percutaneous RFA was technically successful in all 83 patients. Two patients in group one (4.8%) and one patient in group two (2.4%) manifested residual enhancement 3 months post RFA. There was no significant difference in the local recurrence rate between the two groups. At 4.0 ± 1.8 for group one and 3.4 ± 1.9 for group two, the VAS score was not significantly different. Major fentanyl or diazepam toxicity was recorded in 11 patients (24.4%) in group one and two patients (4.8%) in group two; the difference was statistically significant (P < 0.01).
CONCLUSION: The continuous infusion of fentanyl provided effective and safe analgesia in HCC patients undergoing percutaneous RFA. © The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Pain control; hepatocellular carcinoma; intravenous fentanyl delivery; percutaneous radiofrequency ablation

Mesh:

Substances:

Year:  2014        PMID: 24413224     DOI: 10.1177/0284185113519623

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  6 in total

1.  Ablation protocols and ancillary procedures in tumor ablation therapy: consensus from Japanese experts.

Authors:  Masaya Miyazaki; Toshihiro Iguchi; Haruyuki Takaki; Takashi Yamanaka; Yoshitaka Tamura; Hiroyuki Tokue; Yozo Sato; Osamu Ikeda; Tadashi Shimizu; Koichiro Yamakado
Journal:  Jpn J Radiol       Date:  2016-07-23       Impact factor: 2.374

2.  Radiofrequency ablation for single hepatocellular carcinoma 3 cm or less as first-line treatment.

Authors:  Jun Gao; Shao-Hong Wang; Xue-Mei Ding; Wen-Bing Sun; Xiao-Long Li; Zong-Hai Xin; Chun-Min Ning; Shi-Gang Guo
Journal:  World J Gastroenterol       Date:  2015-05-07       Impact factor: 5.742

3.  Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis.

Authors:  LiLi Zhao; Ning Ma; Gaihong Liu; Ni Mao; Fei Chen; Jiao Li
Journal:  Dig Dis Sci       Date:  2021-01-12       Impact factor: 3.199

4.  The Effects of Thoracic Epidural Analgesia during Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Eun-Ji Choi; Yun-Mi Choi; Hye-Jin Kim; Hwoe-Gyeong Ok; Eun-Jung Chang; Hee-Young Kim; Ji-Uk Yoon; Kyung-Hoon Kim; Gyeong-Jo Byeon
Journal:  Pain Res Manag       Date:  2018-11-19       Impact factor: 3.037

5.  Safety and efficacy of pentazocine-midazolam combination for pain and anxiety relief in radiofrequency ablation therapy for hepatocellular carcinoma.

Authors:  Masanori Nakano; Yuichi Torisu; Chika Nakagawa; Kaoru Ueda; Tomoya Kanai; Chisato Saeki; Tsunekazu Oikawa; Masayuki Saruta
Journal:  JGH Open       Date:  2022-07-17

6.  Sedation and Analgesia for Liver Cancer Percutaneous Radiofrequency Ablation: Fentanyl and Oxycodone Comparison.

Authors:  Jiangling Wang; Xiaohong Yuan; Wenjing Guo; Xiaobin Xiang; Qicheng Wu; Man Fang; Wen Zhang; Zewu Ding; Kangjie Xie; Jun Fang; Huidan Zhou; Shuang Fu
Journal:  Int J Med Sci       Date:  2020-08-12       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.